FINNENCE ▪ THE WIRE FILE
THE WIRE · № 65007
News▲ Bullish
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-05 12:15 UTC
LAST UPDATE2026-10-05 12:15 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Early stable-disease data in a CAR-T ovarian trial supports the platform, though it is a single-patient signal.
Anixa reports first stable disease in ovarian CAR-T
CATALYST TO WATCH
Next dose-cohort data readout
MAIN RISK
Single-patient result may not replicate
FULL DISPATCH
First patient in current dose cohort exhibited no progression of her cancer three months after treatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
International Trichology Expert Dr. Kyjuan Brown Unveils AI Scalp Technology and Hair Loss Products at Global Beauty & Trichology Symposium2026-10-05 12:36 UTC
International Trichology Expert Dr. Kyjuan Brown Unveils AI Scalp Technology and Hair Loss Products at Global Beauty & Trichology Symposium2026-10-05 12:36 UTC
→CORRELATIONshares Healthcare
ATI Physical Therapy Launches Innovative Online Scheduling Platform to Make Accessing Care Faster and Easier2026-10-05 12:42 UTC
ATI Physical Therapy Launches Innovative Online Scheduling Platform to Make Accessing Care Faster and Easier2026-10-05 12:42 UTC
→CORRELATIONshares Healthcare
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.2026-10-05 12:45 UTC
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.2026-10-05 12:45 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — Genmab2026-10-05 12:00 UTC
New Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — Genmab2026-10-05 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 — Ambros Therapeutics, Inc.2026-10-05 12:00 UTC
New Phase 3 trial: Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 — Ambros Therapeutics, Inc.2026-10-05 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera — Agios Pharmaceuticals, Inc.2026-10-05 12:00 UTC
New Phase 3 trial: A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera — Agios Pharmaceuticals, Inc.2026-10-05 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.